nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

27.01.2022 | short review

Immunotherapy—another breakthrough in gastrointestinal malignancies

verfasst von: Dr. Monika Lenzi, PD Dr. Thomas Winder, PhD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Summary

Immunotherapy is a breakthrough in different tumor entities. Recently, immunotherapy became an important treatment modality in gastrointestinal (GI) malignancies. In GI malignancies, immunotherapy with or without chemotherapy or targeted agents is revolutionizing the treatment landscape and our daily clinical practice. In this review, we discuss the relevance of immunotherapy in GI malignancies and provide a perspective on promising upcoming treatment strategies.

Vorheriger Artikel Thyroid metastasectomy for deposits from colorectal cancer: case report and non-systematic review

Nächster Artikel Neoadjuvant versus adjuvant management of resectable pancreas cancer: A review of the literature

de Ruiter EJ, Mulder FJ, Koomen BM, et al. Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC). Mod Pathol. 2021;34(6):1125–32. https://doi.org/10.1038/s41379-020-0644-7.CrossRefPubMed

Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD‑1 blockade. Science. 2017;357(6349):409–13. https://doi.org/10.1126/science.aan6733.CrossRefPubMedPubMedCentral

Kato K, Sun J, Shah MA, et al. Pembrolizumab plus chemotherapy vs chemotherapy as first-line therapy in patients with advanced esophageal cancer: the phase III KEYNOTE-590 study. Ann Oncol. 2020;31(4):S1142–S215. https://doi.org/10.1016/j.annonc.2020.08.2298.CrossRef

Chau I, Doki Y, Ajani JA, et al. Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): first results of the checkmate 648 study. J Clin Oncol. 2021;39(18):LBA4001–LBA4001.

Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384(13):1191–203. https://doi.org/10.1056/NEJMoa2032125.CrossRefPubMed

Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40. https://doi.org/10.1016/S0140-6736(21)00797-2.CrossRefPubMedPubMedCentral

Moehler MH, Shitara K, Garrido M, et al. First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): expanded efficacy and safety data from CheckMate 649. J Clin Oncol. 2021;39(15):4002–4002.CrossRef

Janjigian YY, Maron SB, Chatila WK, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020;21(6):821–31. https://doi.org/10.1016/S1470-2045(20)30169-8.CrossRefPubMedPubMedCentral

Rha SY, Lee C‑K, Kim H, et al. Targeting HER2 in combination with anti-PD‑1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: a multi-institutional phase Ib/II trial of first-line triplet regimen (pembrolizumab, trastuzumab, chemotherapy) for HER2-positive advanced gastric cancer (AGC). J Clin Oncol. 2020;38(15):3081–3081.CrossRef

10.

Janjigian YY, Kawazoe A, Yanez PE, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study. J Clin Oncol. 2021;39(15):4013–4013.CrossRef

11.

Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905.CrossRef

12.

Finn RS, Ikeda M, Zhu AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38(26):2960–70.CrossRef

13.

Llovet JM, Kudo M, Cheng A‑L, et al. Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): phase 3 LEAP-002 study. J Clin Oncol. 2019;37(15):TPS4152.CrossRef

14.

André T, Shiu K‑K, Kim TW, et al. Pembrolizumab in microsatellite-instability—high advanced colorectal cancer. N Engl J Med. 2020;383:2207–18.CrossRef

15.

Andre T, Shiu K‑K, Kim TW, et al. Final overall survival for the phase III KN177 study: pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). J Clin Oncol. 2021;39(15):3500–3500.CrossRef

16.

Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus Ipilimumab in DNA mismatch repair–deficient/microsatellite instability–high metastatic colorectal cancer. J Clin Oncol. 2018;36(8):773–9.CrossRef

17.

Gomez-Roca C, Yanez E, Im S‑A, et al. LEAP-005: a phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—results from the colorectal cancer cohort. J Clin Oncol. 2021;39(3):94–94.CrossRef

18.

Smyth EC, Gambardella V, Cervantes A, et al. Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy. Ann Oncol. 2021;32(5):590–9. https://doi.org/10.1016/j.annonc.2021.02.004.CrossRefPubMed

Titel: Immunotherapy—another breakthrough in gastrointestinal malignancies
verfasst von: Dr. Monika Lenzi
PD Dr. Thomas Winder, PhD
Publikationsdatum: 27.01.2022
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 1/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-021-00785-3

Neoadjuvant versus adjuvant management of resectable pancreas cancer: A review of the literature

Open Access
review

Practice-changing strategies in the treatment of esophageal cancer

short review

Clinical challenges in the management of endocrine side effects of immuno-oncological therapies

Open Access
short review

Palliative care: patient’s autonomy in the end-of-life situation

case report

Checkpoint inhibitor pneumonitis: Short review of literature and case report

Open Access
short review

Hepatocellular carcinoma—neoadjuvant systemic and local treatment concepts to improve resectability rates and oncological outcome

short review

Springer Medizin Österreich

Immunotherapy—another breakthrough in gastrointestinal malignancies

Summary

Weitere Artikel der Ausgabe 1/2022

Neoadjuvant versus adjuvant management of resectable pancreas cancer: A review of the literature

Practice-changing strategies in the treatment of esophageal cancer

Clinical challenges in the management of endocrine side effects of immuno-oncological therapies

Palliative care: patient’s autonomy in the end-of-life situation

Checkpoint inhibitor pneumonitis: Short review of literature and case report

Hepatocellular carcinoma—neoadjuvant systemic and local treatment concepts to improve resectability rates and oncological outcome

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neoadjuvant versus adjuvant management of resectable pancreas cancer: A review of the literature

Practice-changing strategies in the treatment of esophageal cancer

Clinical challenges in the management of endocrine side effects of immuno-oncological therapies

Palliative care: patient’s autonomy in the end-of-life situation

Checkpoint inhibitor pneumonitis: Short review of literature and case report

Hepatocellular carcinoma—neoadjuvant systemic and local treatment concepts to improve resectability rates and oncological outcome